Indeed PoS I cleaned all of the accounts this year the RI provided the perfect opportunity along with a very good year across others but that still doesn't mean the business has been "great" for the company. Still hold the title of signing an unprecedented number of big pharma onto deals amongst ASX bio's with the 5th letting the ink dry yesterday but they are yet to see one follow through with the 4 to date walking. Still with a $20M market cap and 30% lower valuation than it was when signing Roche 5 years ago as they walked into the new business model.
Maybe in 2015 we will see change but I wouldn't say it has proven to be a "great business" to date.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)